Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Shares Issued (2016 - 2025)

Adma Biologics (ADMA) has disclosed Shares Issued for 12 consecutive years, with $430000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 2.93% year-over-year to $430000.0, compared with a TTM value of $3.0 million through Dec 2025, down 60.18%, and an annual FY2025 reading of $3.0 million, down 60.18% over the prior year.
  • Shares Issued was $430000.0 for Q4 2025 at Adma Biologics, up from $389000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $64.6 million in Q4 2022 and bottomed at $8000.0 in Q4 2023.
  • Average Shares Issued over 5 years is $12.3 million, with a median of $826500.0 recorded in 2023.
  • The sharpest move saw Shares Issued tumbled 99.99% in 2023, then surged 5437.5% in 2024.
  • Year by year, Shares Issued stood at $53.8 million in 2021, then increased by 20.09% to $64.6 million in 2022, then crashed by 99.99% to $8000.0 in 2023, then soared by 5437.5% to $443000.0 in 2024, then fell by 2.93% to $430000.0 in 2025.
  • Business Quant data shows Shares Issued for ADMA at $430000.0 in Q4 2025, $389000.0 in Q3 2025, and $2.1 million in Q2 2025.